Cellectis S.A.
CLLS
Cena:
$ 3.50
-0.05 (-1.41%)
Valuace
70
Růst
30
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
MONTHLY INFORMATION ON SHARE CAPITAL AND COMPANY VOTING RIGHTS
05-01-2026
(ARTICLE 223-16 OF GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY) (ARTICLE 223-16 OF ...
Více zde
ALLOGENE THERAPEUTICS REPORTS FAVORABLE RESULT FOR SERVIER IN ARBITRATION WITH CELLECTIS
15-12-2025
ARBITRATION RULING REAFFIRMS ALLOGENE'S FULL CONTROL OF CEMACABTAGENE ANSEGEDLEUCEL (CEMA-CEL) DECIS...
Více zde
CELLECTIS ANNOUNCES ARBITRAL DECISION IN DISPUTE WITH SERVIER
15-12-2025
NEW YORK, DEC. 15, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS ...
Více zde
ASH 2025: CELLECTIS PRESENTS DEVELOPMENT PLAN TO FURTHER ENHANCE HIGH RESPONSE RATE OBSERVED FOR ETI-CEL IN R/R NHL
08-12-2025
NEW YORK, DEC. 08, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS ...
Více zde
MONTHLY INFORMATION ON SHARE CAPITAL AND COMPANY VOTING RIGHTS
03-12-2025
(ARTICLE 223-16 OF GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY) (ARTICLE 223-16 OF ...
Více zde
CELLECTIS PUBLISHES NATURE COMMUNICATIONS ARTICLE ON A NON-VIRAL GENE EDITING PROCESS ENABLING EFFICIENT GENE INSERTION IN HEMATOPOIETIC STEM CELLS
19-11-2025
NEW YORK, NOV. 19, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS ...
Více zde
CELLECTIS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
07-11-2025
PRESENTED DATA UNDERSCORE THE POTENTIAL OF LASME-CEL (UCART22) AND ETI-CEL (UCART20X22) TO IMPROVE O...
Více zde
CELLECTIS TO PRESENT A DEVELOPMENT UPDATE FOR ETI-CEL AT ASH 2025
03-11-2025
NEW YORK, NOV. 03, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS - ...
Více zde
CELLECTIS TO REPORT THIRD QUARTER FINANCIAL RESULTS ON NOVEMBER 7, 2025
31-10-2025
NEW YORK, OCT. 31, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS- N...
Více zde
CELLECTIS' R&D DAY HIGHLIGHTS LASME-CEL'S POTENTIAL TO ADDRESS SIGNIFICANT UNMET NEED FOR PATIENTS WITH R/R B-ALL
16-10-2025
○ EFFICACY: ORR OF 68% WITH LASME-CEL PROCESS 2 (N=22), 83% AT RP2D (N=12) AND 100% IN THE TARGET ...
Více zde
CELLECTIS HOSTS R&D DAY TODAY SHOWCASING PIPELINE PROGRESS AND LONG-TERM VALUE DRIVERS
16-10-2025
NEW YORK, OCT. 16, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS - ...
Více zde
CELLECTIS TO PRESENT DATA ON NON-VIRAL GENE THERAPY AND TALE BASE EDITORS AT THE ESGCT ANNUAL CONGRESS
07-10-2025
NEW YORK, OCT. 07, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE "COMPANY") (EURONEXT GROWTH: ALCLS - NASD...
Více zde
CELLECTIS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS & BUSINESS UPDATES
04-08-2025
NEW YORK, AUG. 04, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS - ...
Více zde
CELLECTIS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 4, 2025
28-07-2025
NEW YORK, JULY 28, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS- N...
Více zde
CELLECTIS REPORTS RESULTS FROM SHAREHOLDERS MEETING HELD ON JUNE 26, 2025
26-06-2025
NEW YORK, JUNE 26, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (EURONEXT GROWTH: ALCLS; NASDAQ: CLLS), A CLIN...
Více zde
CELLECTIS' ANNUAL SHAREHOLDERS GENERAL MEETING TO BE HELD ON JUNE 26, 2025
21-05-2025
NEW YORK, MAY 21, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS - N...
Více zde
CELLECTIS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER 2025
12-05-2025
NEW YORK, MAY 12, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS - N...
Více zde
CELLECTIS TO REPORT FIRST QUARTER FINANCIAL RESULTS ON MAY 12, 2025
06-05-2025
NEW YORK, MAY 06, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS- NA...
Více zde
CELLECTIS PRESENTS NON-VIRAL GENE EDITING AND BASE EDITING INNOVATION AT THE ASGCT ANNUAL MEETING
28-04-2025
NEW YORK, APRIL 28, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS -...
Více zde
CELLECTIS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2024 AND PROVIDES A BUSINESS UPDATE
13-03-2025
○ UCART22 PHASE 1 DATASET AND LATE-STAGE DEVELOPMENT STRATEGY EXPECTED IN THE THIRD QUARTER OF 202...
Více zde
CELLECTIS TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ON MARCH 13, 2025
07-03-2025
NEW YORK, MARCH 07, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS-...
Více zde
CELLECTIS PRESENTS ‘SMART CAR T' STRATEGY TO ENHANCE EFFICACY AGAINST SOLID TUMORS AT AACR-IO 2025
24-02-2025
NEW YORK, FEB. 24, 2025 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS - ...
Více zde
CELLECTIS ANNOUNCES THE DRAWDOWN OF THE THIRD TRANCHE OF €5 MILLION UNDER THE CREDIT FACILITY AGREEMENT ENTERED WITH THE EUROPEAN INVESTMENT BANK (EIB)
10-12-2024
NEW YORK, DEC. 10, 2024 (GLOBE NEWSWIRE) -- CELLECTIS (EURONEXT GROWTH: ALCLS – NASDAQ: CLLS) (THE...
Více zde
CELLECTIS PRESENTS MULTIPLE STRATEGIES TO ENHANCE CAR T-CELL EFFICACY IN SOLID TUMORS AT THE SITC ANNUAL MEETING
05-11-2024
NEW YORK, NOV. 05, 2024 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS ...
Více zde
CELLECTIS PROVIDES BUSINESS UPDATES AND FINANCIAL RESULTS FOR THIRD QUARTER 2024
04-11-2024
NEW YORK, NOV. 04, 2024 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS - ...
Více zde
CELLECTIS TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON NOVEMBER 4, 2024
30-10-2024
NEW YORK, OCT. 30, 2024 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS-...
Více zde
CELLECTIS TO PRESENT DATA ON TALE-BASE EDITORS AND NON-VIRAL GENE THERAPY AT THE ESGCT 31ST ANNUAL CONGRESS
22-10-2024
NEW YORK, OCT. 22, 2024 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS - ...
Více zde
CELLECTIS PRESENTS PRE-CLINICAL EVIDENCE OF MUC1 CAR T-CELLS REDUCING TRIPLE-NEGATIVE BREAST CANCER WHILE PRESERVING SAFETY
03-09-2024
NEW YORK, SEPT. 03, 2024 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS -...
Více zde
CELLECTIS PUBLISHES A MOLECULAR THERAPY ARTICLE ON A SMART DUAL CAR T-CELL APPROACH FOR TREATING RECALCITRANT SOLID TUMORS
26-08-2024
NEW YORK, AUG. 26, 2024 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS - ...
Více zde
CELLECTIS APPOINTS DR. ADRIAN KILCOYNE AS CHIEF MEDICAL OFFICER
07-08-2024
NEW YORK, AUG. 07, 2024 (GLOBE NEWSWIRE) -- CELLECTIS (THE “COMPANY”) (EURONEXT GROWTH: ALCLS - ...
Více zde
Dokumenty nejsou k dispozici
